Special remarks: The DEMEDITEC Measles IgM Antibody ELISA Test Kit has been designed for the the detection and the quantitative determination of specific IgM antibodies against Measles in serum and plasma.
The antigen used for coating the plates is the strain Edmonston (ATCC VR-24).

Measles is a highly contagious viral disease characterized by a clinically distinct prodrome of fever, coryza, conjunctivitis, cough and a pathognomic exanthem (Koplik`s spots). The disease is the re­sult of infection with the Measles Virus, genus Morbillivirus of the family Paramyxoviridae.Ten to twelve days after infection, the most prominent and characteristic prodromal symptoms ap­pear: coryza; a persistant barking cough; keratoconjunctivitis, often with photophobia; and fever. Generally lymphadenopathy and splenomegaly are also frequent. During this period, Koplik`s spots appear on the bucal mucosa that rapidly spread involving the entire mucous membrane. These spots are usually gone by the time the skin rash reaches its peak. The rash of Measles appears after a 3- to 5-days prodrome, some 14 days after exposure. The rash quickly becomes maculopapular and spreads rapidly over the face, neck, trunk and extremities during the next three days. At its height, the eruption has generally deepened to a redish purple and may be associated with edema of the skin. Complications are: otitis media, pneumonia and encephalitis. Measles have a more severe ex­pression in younger or undernourished children with a higher incidence of hemorrhage Measles, with 5% to 10% of lethal cases.In people that have been vaccinated with inactive virus (before 1968), the infection can have severe manifestations as: pneumonia, peripheral edema, pleural effusion and atypical rash. Measles are one of the most contagious infectious diseases. The virus spreads through droplets emanating from the respiratory tract of infected persons or by direct contact. The incidence of Measles has declined since the introduction of vaccination programs.

In order to avoid interference of rheumatoid factors, it is highly recommended that patient sera should be treated with RF absorbent (Cat.No. DE-MJS02). Alternatively, positive results can be confirmed in a second test run in the presence of RF adsorbent. Do not pre-treat the controls or standards with RF absorbent!